Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **misfolded prion protein** (PrP^Sc) is a pathogenic, beta-sheet–rich conformational isoform of the normal cellular prion protein (PrP^C), found mainly on neuronal membranes[2][4][1]. PrP^Sc induces normal PrP^C to adopt its misfolded, aggregation-prone structure, resulting in fibrillar amyloid deposits that disrupt brain function and ultimately cause fatal neurodegeneration, characteristic of prion diseases such as Creutzfeldt-Jakob disease and bovine spongiform encephalopathy[2][1][6]. This aberrant, self-propagating protein aggregate acts as both the disease agent and the target for experimental therapies, with current drug research focused on blocking aggregation and enhancing clearance or stabilization of native PrP. There are no approved disease-modifying drugs for prion diseases, and diagnosis relies largely on detection of PrP^Sc as a biomarker of disease progression[3][4][2].
Antibodies: Binding to PrP^Sc to prevent or reverse misfolding/aggregation[3] Small molecules: Inhibition of prion aggregation, stabilization of native conformation[3]
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prion protein (misfolded form, also called PrP^Sc) (PrP^Sc).